Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02963831 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
A Phase 1 study, sponsored by Ludwig Institute for Cancer Research.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT02963831 is a Phase 1 study that has completed, run by Ludwig Institute for Cancer Research. The registered enrollment target is 67 participants.
The verdict
NCT02963831, a Phase 1 study, has completed, sponsored by Ludwig Institute for Cancer Research.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
This is a two-part Phase 1/2 dose escalation and dose expansion study of an Adenovirus Vector (Ad5/3-D24-GMCSF), Expressing GM-CSF (GM-CSF-encoding adenovirus), ONCOS-102, in combination with anti-programmed death ligand-1 (PD-L1) antibody, durvalumab, in adult subjects with peritoneal disease who have failed prior standard chemotherapy and have histologically confirmed epithelial ovarian cancer or metastatic colorectal cancer.
Interventions
- DRUG Cyclophosphamide
- DRUG Durvalumab
- BIOLOGICAL ONCOS-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2017-09-07 |
| Est. Completion | 2022-06-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02963831
The ClinicalTrials.gov registry entry for NCT02963831 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ludwig Institute for Cancer Research, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT02963831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02963831 about?
NCT02963831 is a clinical study titled "A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies". This is a two-part Phase 1/2 dose escalation and dose expansion study of an Adenovirus Vector (Ad5/3-D24-GMCSF), Expressing GM-CSF (GM-CSF-encoding adenovirus), ONCOS-102, in combination with anti-programmed death ligand-1 (PD-L1) antibody, durvalumab, in adult subjects with peritoneal disease who h...
What is the current status of trial NCT02963831?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2017-09-07. Estimated completion is 2022-06-25.
What interventions are being tested in trial NCT02963831?
The interventions under investigation include: Cyclophosphamide (DRUG), Durvalumab (DRUG), ONCOS-102 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02963831?
This trial is sponsored by Ludwig Institute for Cancer Research, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.